The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival
- 1 July 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 35 (7), 2114-2118
- https://doi.org/10.1038/s41375-020-01078-0
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Global Burden of Multiple MyelomaJAMA Oncology, 2018
- Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cellsNature Genetics, 2017
- Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1Blood, 2016
- An Inducible Lentiviral Guide RNA Platform Enables the Identification of Tumor-Essential Genes and Tumor-Promoting Mutations In VivoCell Reports, 2015
- IRF4 addiction in multiple myelomaNature, 2008
- A Signaling Pathway Mediating Downregulation of BCL6 in Germinal Center B Cells Is Blocked by BCL6 Gene Alterations in B Cell LymphomaCancer Cell, 2007
- Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and DeathScience, 2001
- The Combined Functions of Proapoptotic Bcl-2 Family Members Bak and Bax Are Essential for Normal Development of Multiple TissuesMolecular Cell, 2000
- Pip, a lymphoid-restricted IRF, contains a regulatory domain that is important for autoinhibition and ternary complex formation with the Ets factor PU.1.Genes & Development, 1996
- A Novel Interferon Regulatory Factor Family Transcription Factor, ICSAT/Pip/LSIRF, That Negatively Regulates the Activity of Interferon-Regulated GenesMolecular and Cellular Biology, 1996